ClinicalTrials.gg
CompletedNCT03265002EFIGIUpdated Mar 25, 2020

Fibre and Gas in Irritable Bowel Syndrome

An interventional study of Placebo and Inulin in Irritable Bowel Syndrome, sponsored by University of Nottingham. Completed at 1 site in United Kingdom. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Irritable Bowel Syndrome by University of Nottingham — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · University of Nottingham.

Enrollment
12th of 15
19 · median 35
Started
2018
the only one that year
No phase
13 of 17
2 open now
Registered
11th of 17
by date

Among the 17 studies in Irritable Bowel Syndrome by University of Nottingham, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 13 with no phase, and was the 11th registered.

Irritable Bowel Syndrome

1,120 studies on the registry are indexed under Irritable Bowel Syndrome; 211 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

2 of the 17 studies in Irritable Bowel Syndrome by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 130 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 85 (65%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Irritable Bowel Syndrome by University of Nottingham, or all of them as a file.
02

Study summary

The aim of the study is to investigate how dietary fibre combinations affects gut physiology, particularly colonic gas production. Comparisons will be made between a single fermentable fibre (inulin), a non-fermentable fibre (psyllium) and a combination of the two. The study will also explore differences in response between diarrhoea-predominant and constipation-predominant IBS (IBS-D and IBS-C) respectively.

The participants will have a preliminary meeting to ensure they are eligible, then will attend the MRI department on 4 occasions separated by at least 1 week. They will ingest a drink with the fibre product mixed in, and will have 8 MRI scans (each lasting approximately 15 minutes).

Read the detailed description

The aim of the study is to investigate how dietary fibre combinations affects gut physiology, particularly colonic gas production. Comparisons will be made between a single fermentable fibre (inulin), a non-fermentable fibre (psyllium) and a combination of the two. The study will also explore differences in response between diarrhoea-predominant and constipation-predominant IBS (IBS-D and IBS-C) respectively.

This is a single-centre, 4-period, 4-treatment, placebo-controlled, crossover trial. Each treatment will be taken once by each participant, with randomisation of treatment order.

The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious.

Randomisation All participants will take all 4 fibre/ placebo preparations in this crossover trial but the order in which the participants take them will be randomised. The randomisation will be undertaken by a member of the research division who is independent of the study using the remote, online, open source software www.randomization.com. The resulting code will be retained by staff responsible for food preparation in paper form, and will not be shared with the investigator team. A paper copy will be kept by the CI in a sealed envelope.

On enrolment to the study, participants will be allotted the next available randomization sequence. No stratification is needed as in a crossover design participants act as their own controls. There will be a washout period of at least one week between each study day to minimise any carryover effect.

Expected duration of participant participation Study participants will be participating in the study for 6-8 weeks. Women will not be scanned during their menstrual period to avoid confounding of symptom responses.

The study consists of 5 visits to the Queens Medical Centre, Nottingham (QMC). Visits will be in University departments embedded in the hospital, either in the Nottingham Digestive Diseases Centre (NDDC) or the Level A annex of the Sir Peter Mansfield Imaging Centre (SPMIC).

The first visit will be to take consent, assess eligibility and record baseline covariates of interest. All subsequent visits will MRI study days, where participants will undergo a series of MRI scans and other assessments.

Visit 1 This visit will last around 30 minutes. The researcher will confirm that the potential participant has understood the information sheet and answer any remaining questions. The participant will then be assessed for eligibility against the criteria previously set out. If eligibility is confirmed, participants will be asked for details of current medication use including contraception, smoking status, and significant past medical history. Height and weight will be recorded. Participants will complete the Hospital Anxiety and Depression Scale and the Patient Health Questionnaire-12. These questionnaires measure psychological traits that have been associated with symptom response in IBS and so will be relevant covariates.

Participants will then begin a 7-day screening diary of bowel habit and symptoms. This will be used to confirm frequency of IBS symptoms and IBS subtype. Participants will complete the Rome IV diagnostic questionnaire as part of their eligibility assessment. If there is a discrepancy between diary data and participant report on the Rome IV questionnaire, then the PI may decide to exclude the participant. To reduce patient burden, it will be acceptable to return completed diaries by post (prepaid envelope), by electronic communication (scan or photo), or in person.

Participants will also be informed that their GP will be contacted, both to inform them of the subject's participation and to confirm medical details where required.

Once eligibility has been confirmed, the Participant will be enrolled and randomised to a sequence of treatments. These will be administered during Visits 2 - 5. Participants will be asked to minimise their intake of fermentable carbohydrates on the day preceding each of these visits in addition to having a standardised evening meal. A dietary advice sheet will be provided.

Visits 2 - 5: MRI Study Days MRI study days will take place in the level A annex of the SPMIC, in the QMC. Visits will be at least 1 week apart to minimise any carryover effect. Participants will fast from 8pm on the evening before the Study Day. Water will be permitted after 8pm. On the morning of the Study Day participants will not eat or drink, other than a few sips of water to assist swallowing of essential medicines.

It will be confirmed that participants remain safe, eligible and willing to take part. The participants will change into surgical scrubs, in line with scanning policy and will then complete the first set of assessments.

The assessments will be:

  1. Report of gastrointestinal symptoms. Symptoms of wind/ flatulence, bloating and abdominal pain will be scored on a 7-point scale, 0 - 3 in half-integer intervals(5).
  2. Measurement of breath hydrogen and methane content from a single forced exhalation, using the GastroCheck device (Bedfont, UK).
  3. An MRI scan including various scan sequences (See MRI Analysis section)

After fasting assessment participants will ingest a Test Drink. This will comprise still water made up to 500mL with 50mL lemon juice (PLj, Holland\&Barrett, UK), into which the test supplement will be mixed.

The Test Fibres used will be:

A. 20g Inulin B. 20g Inulin and 20g psyllium C. 20g psyllium D. 20g dextrose (0g fibre content - placebo control)

The test drink will be administered in 2 x 250mL portions to prevent swelling of fibres. Participants will be given 10 minutes to consume the total 500mls.

Assessments will be repeated immediately after ingestion, then at intervals post-ingestion as shown in the schematic. Breath symptoms will be measured every 30 minutes for 2 hours, then hourly. MRIs will be taken immediately post ingestion, then hourly for 6 hours. After 3 hours a meal will be provided, designed to be low in fermentable carbohydrate and fibre. This will stimulate gut motility and movement of small bowel content into the colon. The whole Study Day will last around 8 hours.

At the end of the Study Day participants will be asked for an overall rating of their symptoms throughout the day, and an assessment of product acceptability on the basis of their experience (0 - 100 visual analogue scale).

In between assessments participants will be provided with a comfortable sitting area which is part of the level A annex. The participants will be advised to bring material such as magazines, books or electronic devices for entertainment. Guest access to the university's wireless internet (wifi) network will be available.

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • fibre
  • inulin
  • psyllium
  • small bowel MRI
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to give
  • Fulfilment of the Rome IV criteria for Irritable Bowel Syndrome for at least 3 months:

    • Abdominal pain at least two or more days per week.
    • Pain associated with two or more of the following:

      • Related to defecation on at least ≥30% of occasions
      • Associated with a change in frequency of stool on ≥30% of occasions
      • Associated with a change in form (appearance) of stool on ≥30% of occasions
    • Symptom onset at least 6 months prior to diagnosis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy declared by candidate
  • for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
  • Inability to lie flat or exceed scanner limits of weight \<120kg
  • Unwilling to cease use of supplementary fibre or osmotic laxatives for the duration of the study
  • Unable to stop drugs known to alter GI motility or transit including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists or osmotic laxatives for 2 days before, and during, MRI study days.

    • Selective serotonin reuptake inhibitors and low dose tricyclic antidepressants will be recorded but will not be an exclusion criteria
  • Reported alcohol intake of >28 units/ week with daily drinking
  • Intention to change smoking behaviour during the study
  • History declared by the candidate of other pre-existing gastrointestinal disorders, including but not limited to:

    • Inflammatory Bowel Disease
    • Coeliac Disease
    • Pancreatitis
    • Gallstone disease (biliary colic, cholecystitis; asymptomatic presence of gallstones permitted)
    • Complicated diverticulitis (asymptomatic presence of diverticula permitted)
    • Cancer of the gastrointestinal tract
    • Gastroparesis
    • Other functional gastrointestinal disorders will be permitted as they frequently co-exist with IBS.
  • Any reported history of gastrointestinal resection (excluding appendicectomy or cholecystectomy)
  • Presence of an intestinal stoma
  • Poor understanding of English language
  • Participation of any medical trials for the past 3 months
  • Judgement by the PI that the candidate who will be unable to comply with the full study protocol e.g. Diabetes, severe
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Ingestion of 500ml water with 50ml lemon juice and 20g dextrose

    Dietary Supplement: Placebo

  • Experimental
    Inulin

    Ingestion of 500ml water with 50ml lemon juice and 20g inulin

    Dietary Supplement: Inulin

  • Active comparator
    Psyllium

    Ingestion of 500ml water with 50ml lemon juice and 20g psyllium

    Dietary Supplement: Psyllium

  • Active comparator
    Inulin and Psyllium

    Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium

    Dietary Supplement: Inulin and psyllium

Interventions

  • Dietary supplementPlacebo

    Ingestion of 500ml water with 50ml lemon juice and 20g dextrose

  • Dietary supplementInulin

    Ingestion of 500ml water with 50ml lemon juice and 20g inulin

  • Dietary supplementPsyllium

    Ingestion of 500ml water with 50ml lemon juice and 20g psyllium

  • Dietary supplementInulin and psyllium

    Drug pages: Inulin · Psyllium

    Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium

06

What researchers measure

Primary outcomes

  1. Change from the baseline in colonic gas

    in arbitrary units measured by MRI

    Time frame: baseline, 0, 1, 2, 3, 4, 5 and 6 hours post ingestion of the fibre drink

Secondary outcomes

  1. Change from the baseline in colonic volume

    in mL measured by MRI

    Time frame: baseline, 0, 1, 2, 3, 4, 5 and 6 hours post ingestion of the fibre drink

  2. Change from the baseline in small bowel water content

    in mL measured by MRI

    Time frame: baseline, 0, 1, 2, 3, 4, 5 and 6 hours post ingestion of the fibre drink

  3. Change from the baseline in breath hydrogen

    in parts per million using the GastroCheck device

    Time frame: baseline, 0mins, 30mins, 1 hour, 90mins, 2 hours, 3, 4, 5 and 6 hours post ingestion of fibre drink

  4. Change from the baseline in severity of pain, bloating and flatulence

    assessed by the Gastrointestinal Symptom Rating Scale, using a 7-point scale

    Time frame: baseline, 0mins, 30mins, 1 hour, 90mins, 2 hours, 3, 4, 5 and 6 hours post ingestion of fibre drink

Other outcomes

  1. Product acceptability

    gained by questionnaire

    Time frame: throughout the study completion, measured after the 6 hour postprandial measurements.

  2. Change from the baseline in contractility of the ascending colon

    assessed by the MRI motility index

    Time frame: baseline, 0, 1, 2, 3, 4, 5 and 6 hours post ingestion of the fibre drink

  3. breath methane

    in parts per million using the GastroCheck device

    Time frame: baseline, 0mins, 30mins, 1 hour, 90mins, 2 hours, 3, 4, 5 and 6 hours post ingestion of fibre drink

07

Study locations

1 site
  • University of Nottingham
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
08

References and documents

Publications

  • Major G, Pritchard S, Murray K, Alappadan JP, Hoad CL, Marciani L, Gowland P, Spiller R. Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. Gastroenterology. 2017 Jan;152(1):124-133.e2. doi: 10.1053/j.gastro.2016.09.062. Epub 2016 Oct 14. PubMed 27746233 ↗
  • Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P, Marciani L, Gill SK, Warren FJ, Rossi M, Remes-Troche JM, Whelan K, Spiller RC. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut. 2022 May;71(5):919-927. doi: 10.1136/gutjnl-2021-324784. Epub 2021 Aug 5. PubMed 34353864 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2019, 19 months.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 19 months is close to that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 29, 2017
StartActual
Mar 8, 2018
Primary completionActual
Oct 16, 2019
CompletionActual
Oct 16, 2019
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03265002
Responsible party
Sponsor
First posted
Aug 29, 2017
Start date
Mar 8, 2018
Primary completion
Oct 16, 2019
Completion
Oct 16, 2019
Last update
Mar 25, 2020

Study contacts

Robin Spiller, Ph, BMBS
study chair · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inulin

Start the discussion